Souad Mahmoud Alokla

Dr. Souad Mahmoud Alokla

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1999 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
SASouad Mahmoud Alokla
Souad Mahmoud Alokla
CCChristian Chatenay-Rivauday
Christian Chatenay-Rivauday
JKJean-Paul Klein
Jean-Paul Klein
DWDominique Wachsmann
Dominique Wachsmann
Using human endothelial cells, we define a mechanism that accounts for the induction of interleukin 8 (IL‐8) by protein I/IIf, an adhesin from Streptococcus mutans serotype f. We report that protein ...

2 August 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ATAya Twair
Aya Twair
SASouad Mahmoud Alokla
Souad Mahmoud Alokla
MZMoutaz Zarkawi
Moutaz Zarkawi
AAAbdul Qader Abbady
Abdul Qader Abbady

1 August 1998 in Cellular Immunology
Verified
Journal Article
Closed access
AVAline Vernier-Georgenthum
Aline Vernier-Georgenthum
SASouad Mahmoud Alokla
Souad Mahmoud Alokla
BGBénédicte Gourieux
Bénédicte Gourieux
JKJean-Paul Klein
Jean-Paul Klein
DWDominique Wachsmann
Dominique Wachsmann

SASouad Mahmoud Alokla
Souad Mahmoud Alokla
FRFatima Al Zahra Khamis Al Rasbi
Fatima Al Zahra Khamis Al Rasbi
HMHawida Said Al Marhubi
Hawida Said Al Marhubi
SMShima Salim Al Mataani
Shima Salim Al Mataani
YSYusra Mohammed Al Sawai
Yusra Mohammed Al Sawai
AAAbdul Qader Abbady
Abdul Qader Abbady
Background: Asthma is a widespread chronic respiratory disease that poses a significant public health challenge. The current study investigated the associations between air pollution and asthma severity among individuals residing near the Sohar industrial port (SIP) in Oman. Despite the presence of multiple major industrial complexes in Oman, limited knowledge regarding their impact on respiratory health is accredited. Hence, the primary objective of this study is to offer valuable insights into the respiratory health consequences of industrial air pollution in Al Batinah North. Methods: The state health clinics’ records for patient visits related to asthma were collected for the timeframe spanning 2014 to 2022. Exposure was defined as the distance from the SIP, Majan Industerial Area (MIA), and Sohar Industerial Zone (SIZ) to determine high-, intermediate-, and low-exposure zones (12 km, respectively). Exposure effect modifications by age, gender, and smoking status were also examined. Results: The conducted cross-sectional study of 410 patients (46.1% males and 53.9% females) living in over 17 areas around SIP revealed that 73.2% of asthmatics were under 50 years old, with severity significantly associated with closeness to the port. Risk ratios were estimated to be (RR:2.42; CI95%: 1.01–5.78), (RR:1.91; CI95%: 1.01–3.6), and (RR:1.68; CI95%: 0.92–3.09) for SIP, MIP, and SIZ areas, respectively, compared to the control area. Falaj Al Qabail (6.4 km) and Majees (6 km) had the highest number of asthma patients (N 69 and N 72) and highest percentages of severe asthma cases among these patients (28% and 24%) with significant risk ratios (RR:2.97; CI95%: 1.19–7.45 and RR:2.55; CI95%: 1.00–6.48), correspondingly. Moreover, severe asthma prevalence peaked in the 25–50 age group (RR:2.05; CI95%: 1.26–3.33), and this linkage between asthma and age was much more pronounced in males than females. Smoking and exposure to certain contaminants (dust and smoke) also increased the risk of severe asthma symptoms, but their effects were less important in the high-risk zone, suggesting much more important risk factors. A neural network model accurately predicted asthma risk (94.8% accuracy), with proximity to SIP as the most influential predictor. Conclusions: This study highlights the high asthma burden near SIP, linked to port proximity, smoking, and wind direction as major risk factors. These findings inform vital public health policies to reduce air pollution and improve respiratory health in the region, prompting national policy review.

27 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BBbasem battah
basem battah
LSLama Shbibe
Lama Shbibe
OAOsama Ahmad
Osama Ahmad
CSChadi Soukkarieh
Chadi Soukkarieh
SASouad Mahmoud Alokla
Souad Mahmoud Alokla
Matthew Gavino DonaduMatthew Gavino Donadu
Matthew Gavino Donadu
The use of essential oil (EO) in treating infected wounds is still challenging. A lot of effort has been made to make such an application more convenient. Recently, microneedles (MNDs) have been considered as a smart dermal delivery system to overcome the poor absorption and distribution, low bioavailability, and skin penetration of some drugs. The aim of our study is to evaluate the wound healing activity of juniper-EO-loaded MNDs (EO MNDs) against wounds with bacterial and fungal infection. The Polyvinylpyrrolidone (PVP) MNDs were prepared using the gel-filled mold technique and loaded with juniper EO. In vivo models were created and wounds on rats were infected with two clinically isolated bacterial strains Pseudomonas aeruginosa and Staphylococcus aureus. Furthermore, Candida albicans was used to mimic fungal infection and juniper EO MNDs were tested. The obtained results showed an improvement in wound healing which started from the third day after application of the juniper EO MNDs, and at the sixth day post-infection, the treated wounds were significantly smaller than untreated wounds. A complete healing was shown by the 12th day after infection. Furthermore, our cytotoxicity results showed a cytotoxic effect of juniper EO MNDs on epithelial cells, which explained the faster wound healing in rats. Our study showed that juniper EO MNDs represent a novel strategy in EO delivery with minimal invasion. Juniper EO MNDs demonstrated significant antimicrobial activity against both the bacterial strains Pseudomonas aeruginosa and Staphylococcus aureus and against one fungal strain, Candida albicans. Finally, application of juniper EO MNDs exerted promising activity in the treatment and healing of wound infection.

31 July 2015 in The Open Microbiology Journal
Verified
Journal Article
Open access
LALamis Al-Homsi
Lamis Al-Homsi
SASouad Mahmoud Alokla
Souad Mahmoud Alokla
AAAbdul Q. Abbady
Abdul Q. Abbady
Mutacin I, a bacteriocin produced bystreptococcus mutans, displays an antimicrobial activity against many gram positive and some gram negative bacteria. Because of its medical importance, production of this short peptide in large scale for future applications is a significant challenge. This work described the improvement of a novel system to produce the recombinant mutacin using fusion protein technology.The short peptide was expressed directly as a fusion protein with a superfolder form of the green florescent protein (sfGFP), resulting in a high yield expression of solublesfGFP-mutacin fusion protein (30 kDa) in the cytoplasm of E. coli. Mutacin was released from the fusion by enzymatic cleavage at the tobacco etch virus (TEV) protease recognition site and separated from the carriersfGFP by nickel affinity and gel filtration chromatography. An additional advantage of this fusion system was tested in the generation of mutacin-specific polyclonal antibodies. Specific anti-mutacin IgGs were affinity purified, and were able to recognize the mutacin-sfGFP fusion protein or the cleaved forms of mutacin.Even though it was efficiently produced (25 mg/L) by this method, pure mutacin was devoid of antibiotic activity. Fourier transform infrared spectroscopy (FTIR) analysis revealed the absence of thioether bonds in the purified mutacin, which are critical for final structure and function of this antibiotic. Determining whether the activity of pure mutacin could be recovered by the reformation of such structures by chemical reaction needs more investigations. The development of this system will provide large quantities of mutacin for future studies and applications as broad spectrum antibacterial peptide.